P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Goffinet, Marine ^a   Tardy, Claudine ^a   Boubekeur, Nadia ^a   Cholez, Guy ^a   Bluteau, Alice ^a   Oniciu, Daniela C ^a   Lalwani, Narendra D ^b   Dasseux, Jean Louis H ^a   Barbaras, Ronald ^a   Baron, Rudi ^a  

^a Cerenis Therapeutics SA   (France)

^b Cerenis Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PURINERGIC P2Y13 RECEPTOR; 6-(1-(2-DIMETHYLAMINOPYRIMIDIN-5-YLMETHYL)PIPERIDIN-4-YL)-2-MORPHOLIN-4-YL-PYRIMIDIN-4-OL; MORPHOLINE DERIVATIVE; P2RY13 PROTEIN, MOUSE; PURINERGIC P2 RECEPTOR; PURINERGIC P2 RECEPTOR AGONIST; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSPORT KINETICS; UPREGULATION; ANIMAL; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; CAROTID ARTERY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEPG2 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE AGGREGATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID ARTERIES; CHOLESTEROL, HDL; DRUG EVALUATION, PRECLINICAL; HEP G2 CELLS; HUMANS; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION; PURINERGIC P2 RECEPTOR AGONISTS; PYRIMIDINES; RECEPTORS, PURINERGIC P2;

EID: 84899728084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095807     Document Type: Article

References (42)

1. Lee JM, Choudhury RP (2010) Atherosclerosis regression and high-density lipoproteins. Expert Rev Cardiovasc Ther 8: 1325-1334.
2. Brown WV, Brewer HB, Rader DJ, Schaefer EJ (2010) HDL as a treatment target. J Clin Lipidol 4: 5-16.
3. Duffy D, Rader DJ (2009) Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 6: 455-463.
4. Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, et al. (2013) The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 19: 3124-3131.
5. Kamanna VS, Kashyap ML (2008) Mechanism of action of niacin. The American journal of cardiology 101: 20B-26B.
6. Goldberg AS, Hegele RA (2012) Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Des Devel Ther 6: 251-259.
7. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 6736: 1-9.
8. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, et al. (2007) LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol 1: 583-592. (Pubitemid 350215511)
9. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, et al. (2012) High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). Journal of the American College of Cardiology 60: 508-516.
10. deGoma EM, Rader DJ (2012) High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? Journal of the American College of Cardiology 60: 517-520.
11. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, et al. (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421: 75-79. (Pubitemid 36077087)
12. Boeynaems JM, Sirtori CR (2010) The unexpected roles of extracellular ADP and P2Y(13) receptor in reverse cholesterol transport. Purinergic Signal 6: 361-363.
13. Jacquet S, Malaval C, Martinez LO, Sak K, Rolland C, et al. (2005) The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell Mol Life Sci 62: 2508-2515. (Pubitemid 41801103)
14. Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, et al. (2010) P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 52: 1477-1483.
15. Martinez LO, Jacquet S, Terce F, Collet X, Perret B, et al. (2004) New insight on the molecular mechanisms of high-density lipoprotein cellular interactions. Cell Mol Life Sci 61: 2343-2360. (Pubitemid 39382026)
16. Kim YC, Lee JS, Sak K, Marteau F, Mamedova L, et al. (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol 70: 266-274. (Pubitemid 40823051)
17. Becker RC, Gurbel PA (2010) Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 103: 535-544.
18. Communi D, Gonzalez NS, Detheux M, Brezillon S, Lannoy V, et al. (2001) Identification of a novel human ADP receptor coupled to G(i). J Biol Chem 276: 41479-41485.
19. Fumagalli M, Trincavelli L, Lecca D, Martini C, Ciana P, et al. (2004) Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. Biochem Pharmacol 68: 113-124. (Pubitemid 38746547)
20. Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72: 137-174.
21. Ishibashi S, Schwarz M, Frykman PK, Herz J, Russell DW (1996) Disruption of cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J Biol Chem 271: 18017-18023. (Pubitemid 26250787)
22. Schwarz M, Lund EG, Setchell KD, Kayden HJ, Zerwekh JE, et al. (1996) Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J Biol Chem 271: 18024-18031. (Pubitemid 26250788)
23. Arnon R, Yoshimura T, Reiss A, Budai K, Lefkowitch JH, et al. (1998) Cholesterol 7-hydroxylase knockout mouse: a model for monohydroxy bile acidrelated neonatal cholestasis. Gastroenterology 115: 1223-1228. (Pubitemid 28485614)
24. Schwartz CC, Halloran LG, Vlahcevic ZR, Gregory DH, Swell L (1978) Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 200: 62-64. (Pubitemid 8302933)
25. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135.
26. deGoma EM, deGoma RL, Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51: 2199-2211. (Pubitemid 351754991)
27. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222-232.
28. Godin D, Ivan E, Johnson C, Magid R, Galis ZS (2000) Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 102: 2861-2866.
29. Ivan E, Khatri JJ, Johnson C, Magid R, Godin D, et al. (2002) Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation 105: 2686-2691. (Pubitemid 34596048)
30. Lessner SM, Martinson DE, Galis ZS (2004) Compensatory vascular remodeling during atherosclerotic lesion growth depends on matrix metalloproteinase-9 activity. Arterioscler Thromb Vasc Biol 24: 2123-2129. (Pubitemid 39482440)
31. Riedmuller K, Metz S, Bonaterra GA, Kelber O, Weiser D, et al. (2010) Cholesterol diet and effect of long-term withdrawal on plaque development and composition in the thoracic aorta of New Zealand White rabbits. Atherosclerosis 210: 407-413.
32. Guendouzi K, Collet X, Perret B, Chap H, Barbaras R (1998) Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). Biochemistry 37: 14974-14980. (Pubitemid 28487608)
33. Chatterjee C, Sparks DL (2012) Extracellular nucleotides inhibit insulin receptor signaling, stimulate autophagy and control lipoprotein secretion. PLoS One 7: e36916.
34. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, et al. (2012) Myocardial infarction accelerates atherosclerosis. Nature 487: 325-329.
35. Turley SD, Dietschy JM (1978) Re-evaluation of the 3 alpha-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 19: 924-928. (Pubitemid 9028249)
36. Bravo E, Botham KM, Mindham MA, Mayes PA, Marinelli T, et al. (1994) Evaluation in vivo of the differential uptake and processing of high-density lipoprotein unesterified cholesterol and cholesteryl ester in the rat. Biochim Biophys Acta 1215: 93-102. (Pubitemid 24345060)
37. Briand F, Tréguier M, André A, Grillot D, Issandou M, et al. (2010) Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. Journal of lipid research 51: 763-770.
38. Usui S, Hara Y, Hosaki S, Okazaki M (2002) A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 43: 805-814. (Pubitemid 34477908)
39. Dayal B, Ertel NH (2002) ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res 1: 375-380. (Pubitemid 36395879)
40. Kuo MS, Kalbfleisch JM, Rutherford P, Gifford-Moore D, Huang XD, et al. (2008) Chemical analysis of atherosclerotic plaque cholesterol combined with histology of the same tissue. J Lipid Res 49: 1353-1363.
41. Barbaras R, Grimaldi P, Negrel R, Ailhaud G (1986) Characterization of highdensity lipoprotein binding and cholesterol efflux in cultured mouse adipose cells. Biochim Biophys Acta 888: 143-156. (Pubitemid 16026198)
42. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, et al. (2007) Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 117: 2216-2224. (Pubitemid 47219566)